Hangzhou Tigermed Consulting (300347) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.019x

Based on the latest financial reports, Hangzhou Tigermed Consulting (300347) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥475.40 Million ≈ $69.57 Million USD) by net assets (CN¥24.71 Billion ≈ $3.62 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Hangzhou Tigermed Consulting for the company's overall valuation and market capitalisation.

Hangzhou Tigermed Consulting - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Hangzhou Tigermed Consulting's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hangzhou Tigermed Consulting Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hangzhou Tigermed Consulting ranked by their cash flow conversion efficiency. Explore 300347 cash flow quality score to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
VSXY NYSE:VSXY	-0.162x
Shenergy Co Ltd SHG:600642	0.067x
News Corp B NASDAQ:NWS	0.024x
Belite Bio Inc ADR NASDAQ:BLTE	0.000x
thyssenkrupp AG F:TKA1	-0.120x
Enact Holdings Inc NASDAQ:ACT	0.042x
Sensata Technologies Holding NV NYSE:ST	0.071x
Coromandel International Limited NSE:COROMANDEL	0.150x

Annual Cash Flow Conversion Efficiency for Hangzhou Tigermed Consulting (2009–2025)

The table below shows the annual cash flow conversion efficiency of Hangzhou Tigermed Consulting from 2009 to 2025. View current stock price of Hangzhou Tigermed Consulting for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥24.26 Billion ≈ $3.55 Billion	CN¥1.12 Billion ≈ $163.61 Million	0.046x	+1.12%
2024-12-31	CN¥24.06 Billion ≈ $3.52 Billion	CN¥1.10 Billion ≈ $160.53 Million	0.046x	-3.10%
2023-12-31	CN¥24.45 Billion ≈ $3.58 Billion	CN¥1.15 Billion ≈ $168.35 Million	0.047x	-21.40%
2022-12-31	CN¥22.68 Billion ≈ $3.32 Billion	CN¥1.36 Billion ≈ $198.65 Million	0.060x	-13.38%
2021-12-31	CN¥20.61 Billion ≈ $3.02 Billion	CN¥1.42 Billion ≈ $208.35 Million	0.069x	+23.56%
2020-12-31	CN¥17.86 Billion ≈ $2.61 Billion	CN¥998.68 Million ≈ $146.14 Million	0.056x	-41.47%
2019-12-31	CN¥5.52 Billion ≈ $807.94 Million	CN¥527.56 Million ≈ $77.20 Million	0.096x	-40.13%
2018-12-31	CN¥3.27 Billion ≈ $478.82 Million	CN¥522.24 Million ≈ $76.42 Million	0.160x	+41.95%
2017-12-31	CN¥2.80 Billion ≈ $409.92 Million	CN¥314.97 Million ≈ $46.09 Million	0.112x	+7.79%
2016-12-31	CN¥1.84 Billion ≈ $269.22 Million	CN¥191.91 Million ≈ $28.08 Million	0.104x	-40.14%
2015-12-31	CN¥1.07 Billion ≈ $155.98 Million	CN¥185.73 Million ≈ $27.18 Million	0.174x	+265.93%
2014-12-31	CN¥916.90 Million ≈ $134.17 Million	CN¥43.66 Million ≈ $6.39 Million	0.048x	-53.36%
2013-12-31	CN¥755.14 Million ≈ $110.50 Million	CN¥77.10 Million ≈ $11.28 Million	0.102x	+373.15%
2012-12-31	CN¥694.32 Million ≈ $101.60 Million	CN¥14.98 Million ≈ $2.19 Million	0.022x	-91.86%
2011-12-31	CN¥146.03 Million ≈ $21.37 Million	CN¥38.69 Million ≈ $5.66 Million	0.265x	-4.53%
2010-12-31	CN¥95.79 Million ≈ $14.02 Million	CN¥26.59 Million ≈ $3.89 Million	0.278x	-44.03%
2009-12-31	CN¥44.26 Million ≈ $6.48 Million	CN¥21.95 Million ≈ $3.21 Million	0.496x	--

About Hangzhou Tigermed Consulting

SHE:300347 China Diagnostics & Research

Market Cap

$6.16 Billion

CN¥42.07 Billion CNY

Market Cap Rank

#3127 Global

#395 in China

Share Price

CN¥57.01

Change (1 day)

+0.37%

52-Week Range

CN¥36.17 - CN¥66.60

All Time High

CN¥43083.62